NASDAQ · PRPO
Healthcare · Medical - Diagnostics & Research
$17.79
Down-$0.31 (-1.71%)
Updated Nov 3, 2026, 10:17 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRPO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
PRPO closed at $17.79 after 21 trading sessions, down 25.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $18.48 | $18.70 | $17.79 | $17.79 | 12.8K |
| Oct 30, 2026 | $19.83 | $19.83 | $17.99 | $18.10 | 25.9K |
| Oct 29, 2026 | $19.00 | $19.99 | $19.00 | $19.35 | 10.96K |
| Oct 28, 2026 | $19.20 | $19.58 | $18.68 | $18.68 | 25.16K |
| Oct 27, 2026 | $19.57 | $19.825 | $18.91 | $18.91 | 19.72K |
| Oct 26, 2026 | $19.765 | $19.84 | $19.10 | $19.35 | 33.26K |
| Oct 23, 2026 | $20.57 | $20.65 | $19.95 | $20.01 | 11.2K |
| Oct 22, 2026 | $21.20 | $21.20 | $20.47 | $20.61 | 27.61K |
| Oct 21, 2026 | $21.79 | $22.45 | $21.03 | $21.25 | 120.28K |
| Oct 20, 2026 | $21.801 | $22.515 | $21.72 | $21.72 | 26.64K |
| Oct 19, 2026 | $21.45 | $22.28 | $21.45 | $21.89 | 23.75K |
| Oct 16, 2026 | $22.29 | $22.50 | $21.375 | $21.375 | 95.13K |
| Oct 15, 2026 | $22.24 | $22.81 | $22.00 | $22.54 | 45.18K |
| Oct 14, 2026 | $22.40 | $23.17 | $22.15 | $22.25 | 42.51K |
| Oct 13, 2026 | $22.57 | $23.005 | $21.94 | $22.59 | 29.99K |
| Oct 12, 2026 | $22.90 | $23.03 | $22.195 | $22.59 | 11.97K |
| Oct 9, 2026 | $23.14 | $23.815 | $22.9625 | $23.12 | 22.2K |
| Oct 8, 2026 | $23.23 | $23.715 | $22.5501 | $23.19 | 117.99K |
| Oct 7, 2026 | $22.95 | $24.03 | $22.935 | $23.52 | 66.44K |
| Oct 6, 2026 | $24.00 | $24.2722 | $23.30 | $23.45 | 18.16K |
| Oct 5, 2026 | $23.105 | $24.12 | $22.90 | $24.00 | 43.47K |
The latest Smart Investors Daily articles mentioning PRPO.
Company
Market Activity
Research & News
PRPO research
Company profile and research snapshot.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 22, 2019 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Conference Call will be held on November 10th, 2026, at 5:00 PM EST NEW HAVEN, CT – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2026 shareholder update call on November 10, 2026, at 5:00 PM ET.
SeekingAlpha · Oct 12, 2026
Precipio (PRPO) stock update: razor/razor-blades cancer diagnostics, insider + Vanguard/BlackRock ownership, breakeven cash flow, 30% growth.
Yahoo · Sep 22, 2026
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Benzinga · Sep 18, 2026
Precipio (NASDAQ:PRPO) held its second-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRPO.
No results
No recent SID articles mention PRPO.
